US Patent Issued to Seattle Children's Hospital on July 28 for "Therapeutic genome editing in Wiskott-Aldrich syndrome and x-linked thrombocytopenia" (Washington Inventors)

ALEXANDRIA, Va., July 28 -- United States Patent no. 12,692,518, issued on July 28, was assigned to Seattle Children's Hospital (Seattle).

"Therapeutic genome editing in Wiskott-Aldrich syndrome and x-linked thrombocytopenia" was invented by David J. Rawlings (Seattle) and Iram Khan (Issaquah, Wash.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Described herein are systems and methods for treating, inhibiting, or ameliorating X-linked disorders including Wiskott-Aldrich Syndrome (WAS) and X-linked thrombocytopenia (XLT) in subjects that have been identified or selected as being ones that would benefit from a therapy to treat, inhibit, or ameliorate WAS or XLT. The systems include nuclease and vector donor c...